Lung Cancer 2018: Progress and Future Directions



This one-day symposium will provide a comprehensive update on recent advances in the care of patients with thoracic malignancies. There is increasing recognition of a gap between evidence-based guidelines and clinical practice, with research demonstrating that up to 40% of patients fail to receive effective therapies and 20% of patients receive therapies that are ineffective or even harmful. Reducing these gaps leads to reduction in patient morbidity and mortality, and decreased health care costs. With the rapid advances in thoracic oncology, this symposium attempts to crystallize current knowledge and provide critical information and key take-home points to the busy practicing clinician involved in the care of patients with thoracic malignancies. Key focus topics will include guidelines to establish an effective clinically oriented smoking cessation program, the changes to lung cancer staging using the IASLC 8th edition guidelines, novel diagnostic tools such as robotic bronchoscopy, patient selection for multi-modality therapy in locally advanced lung cancer including surgical controversies and role of immunotherapy and proton beam radiation in locally advanced lung cancer, advances in the biology and management of small cell lung cancer, and recent advances in immuno-oncology and targeted therapies in lung cancer. The symposium will also focus on strategies to detect and manage toxicities of immunotherapy for nurses and pharmacists. This symposium will review all of the recent advances in a highly interactive case-based discussion format, supported by didactic lectures by thought leaders and other well-respected faculty in each field.

6.25 Interprofessional Continuing Education (IPCE) credits

Venue: The Wink Hotel


December 8, 2018


Washington, D.C. 20037, United States


Website EID=2777/